Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12752193 | 0.97 | KMT2A (0.38) | KMT2AMEN1TDP1TP53MAPT | |
| SCHEMBL12752190 | 0.92 | KMT2A (0.39) | KMT2AMEN1TDP1TP53MAPT | |
| SCHEMBL12752179 | 0.91 | KMT2A (0.41) | KMT2AMEN1TDP1TP53MAPT | |
| SCHEMBL12752399 | 0.90 | KMT2A (0.33) | KMT2AMEN1TDP1TP53MAPT | |
| SCHEMBL12752183 | 0.88 | KMT2A (0.47) | KMT2AMEN1TDP1TP53MAPT | |
| SCHEMBL12752206 | 0.88 | KMT2A (0.39) | KMT2AMEN1TDP1TP53MAPT | |
| SCHEMBL12828858 | 0.87 | KMT2A (0.40) | KMT2AMEN1TDP1TP53MAPT | |
| SCHEMBL12752361 | 0.87 | KDM4E (0.35) | KMT2AMEN1TDP1MAPTKDM4E | |
| SCHEMBL12752252 | 0.86 | KMT2A (0.36) | KMT2AMEN1TDP1TP53MAPT | |
| SCHEMBL12752272 | 0.85 | KMT2A (0.37) | KMT2AMEN1TDP1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | KMT2A 1544/4885MEN1 4798/4885TDP1 160/4885 |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | KMT2A 1544/4885MEN1 4798/4885TDP1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.